As part of Hansa Biopharma's platform strategy and objective to broaden the application of imlifidase as a potential therapy to change the course of IgG-mediated immunological diseases, the Company is exploring high unmet need indications both through Investigator-Sponsored Trials (IST) programs and Hansa-Sponsored trials.

One of the indications Hansa intends to explore further is allogeneic hematopoietic stem cell transplantation (HSCT), also known as "bone-marrow transplantation". Anti-HLA antibodies against the donor may prevent the successful engraftment of donor cells in a patient requiring allogenic HSCT. Allogeneic HSCT is the only curative treatment intervention for most patients with high-risk hematologic malignancies, with over 50,000 transplants performed annually worldwide.

Desensitization treatment of patients with high levels of donor specific antibodies (DSA) prior to allogeneic HSCT transplant is a challenge, and currently there are no approved drugs for managing these patients. Imlifidase may have the potential to transform the standard of care by enabling clinicians to inactivate DSAs prior to transplantation and has thus the potential to enable successful transplantation. Treatment with imlifidase would potentially be a major advancement to currently available treatments